Navigation Links
Takeda presenta la richiesta di autorizzazione all'immissione in commercio nell'Unione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
Date:3/8/2013

Osaka, Giappone, March 8, 2013 /PRNewswire/ --

Takeda Pharmaceutical Company Limited ("Takeda") ha annunciato oggi di aver presentato una richiesta di Autorizzazione all'Immissione in Commercio (AIC) all'Agenzia europea per i medicinali (EMA - European Medicines Agency) per il vedolizumab, un anticorpo monoclonale umanizzato a selettività intestinale in fase sperimentale, destinato al trattamento della malattia di Crohn (MC) e della colite ulcerosa (CU) moderata-grave, le due  malattie infiammatorie intestinali croniche (MICI) più comuni. Se approvato, il vedolizumab potrebbe rappresentare il primo e unico agente biologico a selettività intestinale attualmente sul mercato per le MICI.

"La colite ulcerosa e la malattia di Crohn sono due malattie croniche debilitanti, con notevoli esigenze mediche insoddisfatte, che colpiscono sovente soggetti giovani, nel fiore degli anni", ha dichiarato Asit Parikh , MD, Ph.D, Vice President, General Medicine di Takeda. "Ci incoraggiano i risultati di GEMINI, il programma di sviluppo clinico di fase 3 del vedolizumab, che ha coinvolto circa 3.000 pazienti in quasi 40 Paesi, accreditandosi come il più esteso programma di trial clinico rivolto alle MICI finora realizzato."

In tutto il mondo, sono quasi quattro milioni i pazienti affetti da MICI. Di questi, nell'Unione Europea, più di 500.000 sono affetti da CU e quasi 230.000 da MC. La malattia di Crohn e la colite ulcerosa sono malattie croniche, che determinano l'infiammazione della mucosa del tratto digerente. Mentre lo stato infiammatorio prodotto dalla MC può coinvolgere aree diverse del tratto digerente, la CU colpisce esclusivamente il colon-retto. MC e CU possono essere dolorose e debilitanti, generare complicanze gravi e incidere significativamente sulla qualità di vita dei pazienti.

La presentazione dell'AIC è stata supportata dai risultati degl
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
2. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
3. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
4. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
5. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
6. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
7. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
8. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
9. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
10. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
11. Boston Scientific Updates PREVAIL Late Breaking Clinical Trials Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015 CEFALY Technology , ... stimulation device specifically authorized for use prior to the ... a new PET trial showing that the Cefaly device ... brain in migraine patients, namely the orbitofrontal cortex and ... scan, which is an imaging test of the brain, used a radioactive ...
(Date:6/1/2015)... SETAUKET, N.Y. , June 1, 2015 /PRNewswire/ ... (NASDAQ: HRTX ) today announced positive, top-line ... study.  MAGIC evaluated the efficacy and safety of ... candidate SUSTOL ® (granisetron injection, extended release) ... intravenous (IV) neurokinin-1 (NK 1 ) receptor antagonist ...
(Date:6/1/2015)... 2015   OTC Markets Group Inc. ... financial marketplaces for 10,000 U.S. and global securities, ... Diego -based biopharmaceutical company, on its NASDAQ ... public venture market for entrepreneurial and development stage ... "We,re happy to congratulate OncoSec ...
Breaking Medicine Technology:New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2New cancer therapy study results - MAGIC Trial 2OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
... and drug withdrawal, CHICAGO, May 15, 2007 /PRNewswire/ ... and physicians commissioned by the National,Headache Foundation and ... migraine patients are currently taking potentially,addictive medications that ... by the U.S. Food and Drug Administration for ...
... , LONDON, UK and ATLANTA, US, May 14, ... Inc. (NASDAQ:SCRX) today,announce the successful completion of the ... a calcium ,channel blocking agent for the treatment ... the new Sular formulation is,bioequivalent to Sciele's currently ...
Cached Medicine Technology:Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 2SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 3
(Date:6/2/2015)... 02, 2015 The Radiosurgery Society® ... from the RSSearch® Patient Registry evaluating the treatment ... (SBRT) for the treatment of centrally located primary ... , The study, published in the May, ... included 111 patients with 114 centrally located lung ...
(Date:6/2/2015)... Colorado (PRWEB) June 02, 2015 ... Chief Medical Officer at the Steadman Philippon Research Institute, ... Too Early for Single Sport Specialization? ” This was ... Sports Medicine (AOSSM) Research Committee that was recently published ... data for this project was limited, there is evidence ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Each year, ... Insiders’ Choice Beauty Awards. This year, the organization’s members ... the winner of the QVC® Beauty Quest Award at ... results-driven Micro Emulsion (ME) Technology and 2-in-1 approach to ... Also noting the brand’s loyal consumer and professional fan ...
(Date:6/2/2015)... View, CA (PRWEB) June 02, 2015 ... mandated vaccination schedule for children to attend public or ... Judiciary and Education but bypassed the Appropriations Committee (Sacramento ... floor 25-10 despite contentious hearings. , “We believe ... Personal Belief Exemptions (PBEs) more than it will (the) ...
(Date:6/1/2015)... June 02, 2015 The National ... Wirski as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in business. NAPW is ... boasting more than 700,000 members and over 200 operating ... this prestigious honor,” said NAPW President Star Jones. “Job ...
Breaking Medicine News(10 mins):Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2
... Data that shed new light on,the treatment of ... immune thrombocytopenic purpura, and venous,thrombosis in relation to ... 49th Annual Meeting of the American Society of,Hematology ... this new research,on Saturday, December 8, from 10:00 ...
... is a clear link between GABA a chemical ... in the brain and nicotine dependence, according ... of Neuropsychopharmacology (ACNP) annual meeting. Researchers discovered that nicotine ... could potentially help curb the pleasurable effects of nicotine ...
... link between mitochondria, memory and socialization , FRIDAY, ... respiration deficiencies in mitochondria (the source of energy ... behavior and spatial memory, Japanese researchers report. , ... link between mitochondrial malfunction and mental illness in ...
... more invasive treatment is necessary, researchers say , , FRIDAY, Dec. 7 ... test to detect lung cancer, according to a Duke University Medical ... Dec. 10 issue of the Journal of Clinical Oncology , ... RBP, SCC and AAT -- may provide a simple follow-up for ...
... that we must remain vigilant,in protecting women,s access to ... care professionals who provide that care, WASHINGTON, Dec. ... President and CEO of the National Abortion,Federation, on the ... Albuquerque,NM:, As the professional association of abortion providers, ...
... KING OF PRUSSIA, Pa., Dec. 7 Universal ... that its Board of Directors,authorized an additional 5 ... shares remaining under previously announced authorizations.,Pursuant to the ... time as,conditions allow, may purchase shares on the ...
Cached Medicine News:Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 2Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 3Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 4Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 5Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 6Health News:Study suggests nicotine addiction might be controlled by influencing brain mechanisms 2Health News:Blood Test to Detect Lung Cancer Being Eyed 2
... Savant offers several different two-stage, oil-sealed, rotary ... freeze drying applications. Each pump comes complete ... Kit) and and Oil Mist Filter (EMF-10). ... full gas ballast to keep the oil ...
Produces vacuum pressures required for 96 well kits...
Inquire...
... The Perfect Single Vac ... one 96-well plate in 30 ... with an "open/closed" switch and ... for easy operation. contains vacuum ...
Medicine Products: